Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Federal Trade Commission
Boehringer Ingelheim
UBS
McKinsey
Harvard Business School
QuintilesIMS
Merck
Daiichi Sankyo

Generated: July 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,339,552

« Back to Dashboard

Title:Diclofenac topical formulation
Abstract: The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis.
Inventor(s): Kisak; Ed (San Diego, CA), Singh; Jagat (Toronto, CA)
Assignee: HZNP Limited (Pembroke, BM)
Filing Date:Oct 26, 2015
Application Number:14/922,903
Claims:1. A topical formulation consisting of: diclofenac sodium present at 2% w/w; DMSO present at 40 to 50% w/w; hydroxypropyl cellulose; ethanol present at 23% to 29% w/w; propylene glycol present at 10% to 12% w/w; and water to make 100% w/w, wherein the topical formulation has a viscosity of 500 to 5000 centipoise, and wherein the formulation has a pH of 4 to 10.

2. The topical formulation of claim 1, wherein the concentration of DMSO is 45.5% w/w.

3. The topical formulation of claim 1, wherein the concentration of the propylene glycol is 10% w/w.

4. The topical formulation of claim 2, wherein the concentration of the propylene glycol is 11% w/w.

5. The topical formulation of claim 2, wherein the concentration of the propylene glycol is 12% w/w.

6. The topical formulation of claim 1 wherein the concentration of the hydroxypropyl cellulose is 2.5% w/w.

7. The topical formulation of claim 1, wherein the viscosity is at least 1000 cp.

8. The topical formulation of claim 2, wherein the viscosity is at least 1000 cp.

9. The topical formulation of claim 1, wherein the formulation degrades at less than 1% over 6 months.

10. The topical formulation of claim 2, wherein the formulation degrades at less than 1% over 6 months.

11. A method for treating pain due to osteoarthritis of a knee of a patient in need thereof comprising administering to the knee a topical formulation of claim 1.

12. The method of claim 11, wherein the formulation is topically administered to the knee 2 times per day.

13. A method for treating pain due to osteoarthritis of a knee of a patient in need thereof comprising administering to the knee a topical formulation of claim 2.

14. The method of claim 13, wherein the formulation is topically administered to the knee 2 times per day.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Julphar
AstraZeneca
Baxter
Cerilliant
Merck
Covington
Cipla
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.